Results 51 to 60 of about 11,256 (207)

RAD51 as an immunohistochemistry-based marker of poly(ADP-ribose) polymerase inhibitor resistance in ovarian cancer

Frontiers in Oncology
ObjectiveEffective functional biomarkers that can be readily used in clinical practice to predict poly(ADP-ribose) polymerase inhibitor (PARPi) sensitivity are lacking.
Yoo-Na Kim, Kyeongmin Kim, Kyeongmin Kim, Je-Gun Joung, Sang Wun Kim, Sunghoon Kim, Jung-Yun Lee, Eunhyang Park   +7 more
doaj   +1 more source

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

Molecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis, Jack V. Mills, Wojciech Niedzwiedz, Valentine M. Macaulay   +3 more
wiley   +1 more source

Radiosensitivity Is an Acquired Vulnerability of PARPi-Resistant BRCA1-Deficient Tumors [PDF]

Cancer Research, 2019
Abstract The defect in homologous recombination (HR) found in BRCA1-associated cancers can be therapeutically exploited by treatment with DNA-damaging agents and PARP inhibitors. We and others previously reported that BRCA1-deficient tumors are initially hypersensitive to the inhibition of ...
Marco Barazas, Alessia Gasparini, Yike Huang, Asli Küçükosmanoğlu, Stefano Annunziato, Peter Bouwman, Wendy Sol, Ariena Kersbergen, Natalie Proost, Renske de Korte-Grimmerink, Marieke van de Ven, Jos Jonkers, Gerben R. Borst, Sven Rottenberg   +13 more
openaire   +5 more sources

Finding novel vulnerabilities of hypomorphic BRCA1 alleles

Molecular Oncology, EarlyView.
Synthetic lethality screens performed to identify novel vulnerabilities often model complete gene loss, thereby overlooking patient‐derived hypomorphic mutations. In this study, we have performed genome‐wide CRISPR screens on BRCA1 hypomorphic mutations, showing BRCA1I26A behaves like wild‐type, while BRCA1R1699Q mimics deficiency. Furthermore, we have
Anne Schreuder, Klaas de Lint, Hồ Mỹ Phúc Võ, Mariana M. Góis, Rosalie A. Kampen, Marta San Martin Alonso, Ilse Nootenboom, Veronica Garzero, Tiemen J. Wendel, Rob M. F. Wolthuis, Sylvie M. Noordermeer   +10 more
wiley   +1 more source

Combination of the PARPi and ARSi in advanced castration resistant prostate cancer: a review of the recent phase III trials

Exploration of Targeted Anti-tumor Therapy
Tumors with an impaired ability to repair DNA double-strand breaks by homologous recombination, including those with alterations in breast cancer 1 and 2 (BRCA1 and BRCA2) genes, are very sensitive to blocking DNA single-strand repair by inhibition of ...
Martina Panebianco, Vittore Cereda, Mario Rosario D’Andrea   +2 more
doaj   +1 more source

RSF1‐Dependent PAR Turnover Promotes 53BP1 Liquid Condensate Formation at DNA Damage Sites

Advanced Science, EarlyView.
At sites of DNA damage, RSF1 recruits PARG to accelerate PAR turnover, triggering a switch from PAR‐driven condensates to 53BP1 condensates. This condensate transition enables p53‐dependent gene transcription and coordinates the DNA damage response.
Yungyeong Heo, Yonghyeon Kim, Nangyeong Hwang, Gwanho Sung, Sujin Jo, Yeonhu Lee, Ho‐Chul Kang, Jae‐Ho Lee, Yong Won Choi, Hyeseong Cho, Sunwoo Min   +10 more
wiley   +1 more source

FANCA-deficient cancer cells are sensitized to PARPi and ATRi by homologous recombination-independent mechanisms [PDF]

PARP inhibitors (PARPi) are a class of DNA damage-inducing drugs currently used in the clinic to treat cancers with mutations in BRCA1/2, which show elevated sensitivity to PARPi.
Ellington, Simon
core   +1 more source

Impact of PARP inhibitor maintenance therapy in newly diagnosed advanced epithelial ovarian cancer: A meta-analysis.

PLoS ONE, 2023
ObjectivesThis meta-analysis was undertaken to systematically evaluate the effects of poly (ADP-ribose) polymerase inhibitor (PARPi) maintenance therapy on the survival of newly diagnosed advanced epithelial ovarian cancer (EOC) patients.Methods ...
Banghyun Lee, Suk-Joon Chang, Byung Su Kwon, Joo-Hyuk Son, Myong Cheol Lim, Yun Hwan Kim, Shin-Wha Lee, Chel Hun Choi, Kyung Jin Eoh, Jung-Yun Lee, Dong Hoon Suh, Yong Beom Kim   +11 more
doaj   +1 more source

Loss of CYLD on Chromosome 16q Impairs Homologous Recombination and Genomic Stability Through TIRR Degradation

Advanced Science, EarlyView.
Chromosome 16q loss drives genomic instability through disruption of the CYLD–TIRR–53BP1 axis. CYLD preserves homologous recombination by stabilizing TIRR and limiting 53BP1 accumulation at DNA double‐strand breaks. CYLD deficiency redirects repair toward error‐prone non‐homologous end joining, promotes mutational burden and homologous recombination ...
Mingming Lu, Jialu Kang, Qi Ye, Zixi Wang, Lei Li, Yuzeshi Lei, Leihong Ye, Tianjie Liu, Bin Wang, Tao Liu, Shan Xu, Ke Wang, Yong Zhang, Jian Ma, Lei Li   +14 more
wiley   +1 more source

A one‐pot radiosynthesis of [¹⁸F]PARPi

Journal of Labelled Compounds and Radiopharmaceuticals, 2020
In this paper, we disclose a new strategy for the radiosynthesis of [18F]PARPi from the corresponding, boc‐protected, nitro‐precursor. Using a two‐step procedure, [18F]PARPi could be isolated in radiochemical yields up to 9.6%. The reaction proceeds via an efficient one‐pot, two‐step process, allowing for simplification over previous methods that ...
Thomas C. Wilson, Nagavarakishore Pillarsetty, Thomas Reiner   +2 more
openaire   +3 more sources